VIII. Radioimmunotherapy in malignant lymphoma: an underused tool?

Annals of Oncology

Volumn 22, Issue , 2011, Pages iv51-iv53

  Hagenbeek, A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873369835     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr174     Document Type: Conference Paper

References (25)

1. Witzig, T.E., White, C.A., Wiseman, G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999), 3793–3803.
2. Wiseman, G.A., Gordon, L.I., Multani, P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99 (2002), 4336–4342.
3. Witzig, T.E., Gordon, L.I., Cabanillas, F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002), 2453–2463.
4. Witzig, T.E., Flinn, I.W., Gordon, L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002), 3262–3269.
5. Gordon, L.I., Molina, A., Witzig, T.E., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103 (2004), 4429–4431.
6. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II clinical trial. 2010 ASH Annual Meeting Abstracts. Blood, 116(21), 2010 Abstract 593.
7. Morschhauser, F., Radford, J., Van Hoof, A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26 (2008), 5156–5164.
8. 90Y-Ibritumomab tiuxetan (zevalin) consolidation of first remission in advanced-stage follicular non-Hodgkin's lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized phase III First-line Indolent Trial (FIT) in 414 patients. 2010 ASH Annual Meeting Abstracts. Blood, 116(21), 2010 Abstract 594.
9. 90 Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14 (2008), 7088–7094.
10. McLaughlin, P., Neelapu, S., Fanale, M., et al. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. 2008 ASH Annual Meeting Abstracts. Blood, 112(11), 2008 Abstract 3056a.
11. Hainsworth, J.D., Spiegel, D.R., Markus, T.M., et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 9 (2009), 223–228.
12. Morton, L.M., Curtis, R.E., Linet, M.S., et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 28 (2010), 4935–4944.
13. Kaminski, M.S., Zelenetz, A.D., Press, O.W., et al. Pivotal study of iodine-131-tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001), 3918–3928.
14. Horning, S.J., Younes, A., Jain, V., et al. Efficacy and safety of tositumomab and iodine-131-tositumomab (bexxar) in B-cell lymphoma progressive after rituximab. J Clin Oncol 23 (2005), 712–719.
15. Kaminski, M.S., Tuck, M., Estes, J., et al. 131-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005), 441–449.
16. Kaminski, M., I-131-tositumomab monotherapy as frontline treatment for follicular lymphoma: updated results after a median follow-up of 8 years. ASCO Annual Meeting Abstracts. J Clin Oncol, 25(18S), 2007 Abstract 8033.
17. Leonard, J.P., Coleman, M., Kostakoglu, L., et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23 (2005), 5696–5704.
18. Press, O.W., Unger, J.M., Braziel, R.M., et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: 5-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24 (2006), 4143–4149.
19. Link, B.K., Martin, P., Kaminski, M.S., et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: 8-year follow-up in a multicenter phase II study. J Clin Oncol 28 (2010), 3035–3041.
20. Bennett, J.M., Kaminski, M.S., Leonard, J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myelogenous leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab. Blood 105 (2005), 4576–4582.
21. Hohloch, K., Lankeit, H.K., Zinzani, P.L., et al. Radioimmunotherapy for consolidation and relapse treatment of aggressive B-cell non-Hodgkins lymphoma: an updated analysis of the international RIT-network. 11th International Conference on Malignant Lymphoma. Lugano, 2011 Abstract 97.
22. Karmali, R., Manson, A., Bueschel, K., et al. Phase II study of 2-weekly CHOP + rituximab followed by yttrium-90 ibritumomab tiuxetan (zevalin) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final analysis. 2010 ASH Annual Meeting Abstracts. Blood, 116(21), 2010 Abstract 3947.
23. Krishnan, A., Palmer, J., Nademanee, A., et al. Comparative analysis of autologous hematopoietic cell transplantation with radioimmunotherapy (RIT) based conditioning versus total body irradiation (TBI) for high-risk diffuse large B-cell lymphoma (DLBCL): toxicity and efficacy. 2010 ASH Annual Meeting Abstracts. Blood, 116(21), 2010 Abstract 32.
24. Shimoni, A., Avivi, I., Rowe, J.M., et al. A multi-center prospective randomized study comparing ibritumomab tiuxetan (zevalin) and high-dose BEAM chemotherapy (Z-BEAM) vs BEAM alone as the conditioning regimen prior to autologous stem cell transplantation in patients with aggressive lymphoma: possible advantage for Z-BEAM in low-risk patients. 2010 ASH Annual Meeting Abstracts. Blood, 116(21), 2010 Abstract 686.
25. Hochster, H., Weller, E., Gascoyne, R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG 1496 study. J Clin Oncol 27 (2009), 1607–1614.